Patients were randomly assigned ( 1:1 ) to receive once-daily oral tablets containing 150 mg elvitegravir , 150 mg cobicistat , 200 mg emtricitabine , and 10 mg tenofovir alafenamide ( E/C/F / tenofovir alafenamide ) or 300 mg tenofovir disoproxil fumarate ( E/C/F / tenofovir disoproxil fumarate ) with matching placebo .